

| | | |
|---|-----------------------------------|---|
|  | ACCREDITATION DOCUMENT | F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 162 |
|---|-----------------------------------|---|

Accreditation No: LAB 162

Awarded to

**Drugs Testing Laboratory Punjab, Lahore
Primary and Secondary Healthcare Department 1-Birdwood Road
Lahore, Pakistan.**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **31-08-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **30-08-2024**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

13-12-2022
Date

SD
Director General

| | | |
|---|-----------------------------------|---|
|  | ACCREDITATION DOCUMENT | F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 162 |
|---|-----------------------------------|---|

Testing Laboratory.

Accreditation Scope of Drugs Testing Laboratory Punjab, Lahore
Primary and Secondary Healthcare Department 1-Birdwood Road Lahore,
Pakistan.

Permanent laboratory premises

| Materials/Products tested | Testing field (e.g. environmental testing or mechanical testing) | Types of test/ Properties measured | Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference |
|---|--|---------------------------------------|--|
| Paracetamol Tablets | Pharmaceutical Testing | Identification & Assay | 95 – 105% (BP 2022 Vol-III Pg. No. 1115) UV-Spectrophotometer |
| Paracetamol Suspension | Pharmaceutical Testing | Identification & Assay | 95 – 105% (BP 2022 Vol-III Pg. No. 1113) HPLC method |
| Amoxicillin for Suspension | Pharmaceutical Testing | Identification & Assay | 90 – 120% (USP 2022) HPLC Method |
| Ibuprofen Suspension | Pharmaceutical Testing | Identification & Assay | 95 – 105% (BP 2022 Vol-III Pg. No. 782) HPLC Method |
| Amoxicillin Capsules | Pharmaceutical Testing | Identification & Assay | 90 – 120% (USP 2022) HPLC Method |
| Ceftriaxone Sodium for Inj. | Pharmaceutical Testing | Identification & Assay | 90 – 115% (USP 2022) HPLC Method |
| Sofosbuvir Tablet | Pharmaceutical Testing | Identification & Assay | 90 – 110% (MS) DTLHR-ANA-010 HPLC Method |
| Amlodipine Tablets | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC Method |
| Ipratropium Bromide Nebulization Solution | Pharmaceutical Testing | Identification & Assay | 95 – 110% (BP 2022 Vol-III Pg. No. 817) HPLC Method |
| Liquid Pharmaceutical Dosage Form | Pharmaceutical Testing | Conductivity Testing | 0.1-500µs/cm USP 2022 General Chapter <651> Water Conductivity |
| Pharmaceutical Oral Suspensions | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Oral Solutions | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Injections | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 |

13-12-2022

Date

SD

Director

| | | |
|---|-----------------------------------|---|
|  | ACCREDITATION DOCUMENT | F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 162 |
|---|-----------------------------------|---|

| | | | |
|--|------------------------|------------------------|--|
| | | | Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Infusions | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Topical Solutions | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Ophthalmic Solutions | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Powder for injection | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Ophthalmic Suspension | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Pharmaceutical Powder for oral suspension | Pharmaceutical Testing | pH | USP General Chapter <791>/ BP 2022 Vol-V Pg. No. A286 Appendix V L. Determination of pH Values (pH Range 1-14) |
| Film coated Tablets (≥ 25mg) | Pharmaceutical Testing | Weight Variation | BP 2022 Vol-V Pg. No. A413 Appendix XII C. Consistency of Formulated Preparations |
| Uncoated tablets (≥ 25mg) | Pharmaceutical Testing | Weight Variation | BP 2022 Vol-V Pg. No. A413 Appendix XII C. Consistency of Formulated Preparations |
| Soft Gelatin Capsules (≥ 25mg) | Pharmaceutical Testing | Weight Variation | BP 2022 Vol-V Pg. No. A413 Appendix XII C. Consistency of Formulated Preparations |
| Hard Gelatin Capsules (≥ 25mg) | Pharmaceutical Testing | Weight Variation | BP 2022 Vol-V Pg. No. A413 Appendix XII C. Consistency of Formulated Preparations |
| Tablets & Capsules | Pharmaceutical Testing | Disintegration Testing | (BP 2022 Vol-V Pg. No. A389) Appendix XII A. Disintegration USP2022 <701> Disintegration |
| Tablets | Pharmaceutical Testing | Friability Testing | NMT 1% at 25rpm for 04 min BP 2022 Vol-V Pg. No. A581 Appendix XVII G. Friability Friability Apparatus USP 2022 <1216> Tablet friability |
| Cetirizine Tablets | Pharmaceutical Testing | Dissolution Testing | NLT 80% (USP 2022) Dissolution Testing Apparatus HPLC/ UV-Spectrophotometer |
| Metronidazole infusion | Pharmaceutical Testing | Identification & Assay | 95 – 110% (BP 2022 Vol-III Pg. No. 970) UV-Spectrophotometer |
| Omeprazole Capsule | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC Method |

13-12-2022
Date

SD
Director



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 162

| | | | |
|---|------------------------|------------------------|---|
| Atenolol Tablets | Pharmaceutical Testing | Identification & Assay | 92.5 – 107.5% (BP 2022 Vol-III Pg. No. 178) UV-Spectrophotometer |
| Betamethasone Valerate Raw Material | Pharmaceutical Testing | Identification & Assay | 97 – 103% (USP 2022) HPLC Method |
| Ceftriaxone Sodium Raw Material | Pharmaceutical Testing | Identification & Assay | 96 – 102% (BP 2022 Vol-I Pg. No. 494) HPLC Method |
| Cloxacillin Na Raw Material | Pharmaceutical Testing | Identification & Assay | 95 – 102% (BP 2022 Vol-I Pg. No. 643) HPLC Method |
| Cephadrine Raw Material | Pharmaceutical Testing | Identification & Assay | 900 – 1050µg/mg (USP 2022) HPLC Method |
| Orphenadrine Raw Material | Pharmaceutical Testing | Identification & Assay | 98 – 101.5% (USP 2022) HPLC Method |
| Ampicillin Trihydrate Raw Material | Pharmaceutical Testing | Identification & Assay | 96 – 102% (BP 2022 Vol-I Pg. No. 183) HPLC Method |
| Omeprazole Raw Material | Pharmaceutical Testing | Identification & Assay | 98 – 102% (USP 2022) HPLC Method |
| Cefixime Raw Material | Pharmaceutical Testing | Identification & Assay | 95 – 102% (BP 2022 Vol-I Pg. No. 474) HPLC Method |
| Cephalexin Raw Material | Pharmaceutical Testing | Identification & Assay | 950 – 1030µg/mg (USP 2022) HPLC Method |
| Amoxicillin Raw Material | Pharmaceutical Testing | Identification & Assay | 900 – 1050µg/mg (USP 2022) HPLC Method |
| Metronidazole Raw Material | Pharmaceutical Testing | Identification & Assay | 99 – 101% (USP 2022) HPLC Method |
| Salbutamol (Albuterol) Raw Material | Pharmaceutical Testing | Identification & Assay | 98.5 – 101% (USP 2022) HPLC Method |
| Tenofovir Raw Material | Pharmaceutical Testing | Identification & Assay | 98.5 – 101% (MS) HPLC Method |
| Ribavirin Raw Material | Pharmaceutical Testing | Identification & Assay | 98.9 – 101.5% (USP 2022) HPLC Method |
| Ciprofloxacin HCl Raw Material | Pharmaceutical Testing | Identification & Assay | 98 – 102% (USP 2022) HPLC Method |
| Amoxicillin and Clavulanate Potassium Tablets | Pharmaceutical Testing | Identification & Assay | 90-120 % (USP 2022) HPLC Method |
| Amoxicillin and Clavulanate Potassium Suspension | Pharmaceutical Testing | Identification & Assay | 90-120% of Amoxicillin 90-125% of Clavulanic acid (USP 2022) HPLC Method |
| Amikacin Injection | Pharmaceutical Testing | Identification & Assay | 90 - 110% (BP 2022 Vol-III Pg. No. 136) HPLC Method |
| Propofol Injection | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Levofloxacin Tablets | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Montelukast Sodium Tablets | Pharmaceutical Testing | Identification & Assay | 92.5-107.5% (USP 2022) HPLC Method |

13-12-2022
Date

SD
Director

| | | |
|---|-----------------------------------|---|
|  | ACCREDITATION DOCUMENT | F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 162 |
|---|-----------------------------------|---|

| | | | |
|--|------------------------|--------------------------|--|
| Diclofenac Sodium Tablets | Pharmaceutical Testing | Identification & Assay | 95-105% (BP 2022 Vol-III Pg. No. 520) HPLC Method |
| Losartan Potassium Tablets | Pharmaceutical Testing | Identification & Assay | 95-105% (USP 2022) HPLC Method |
| Glibenclamide Tablets | Pharmaceutical Testing | Identification & Assay | 95-105% (BP 2022 Vol-III Pg. No. 714) HPLC Method |
| Cefixime for oral Suspension | Pharmaceutical Testing | Identification & Assay | 90-120% (USP 2022) HPLC Method |
| Dopamine HCl injection | Pharmaceutical Testing | Identification & Assay | 95-105% (USP 2022) HPLC Method |
| Sodium Chloride Infusion | Pharmaceutical Testing | Assay | 95-105% (BP 2022 Vol-III Pg. No. 1297) Titration Method |
| Levetiracetam Injection | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Sodium Chloride + Dextrose Infusion | Pharmaceutical Testing | Assay of Sodium Chloride | 95-105% (BP 2022 Vol-III Pg. No. 1299) Titration Method |
| Metronidazole Tablets | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Ibuprofen Tablets | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Metformin Tablets | Pharmaceutical Testing | Assay | 95-105% (BP 2022 Vol-III Pg. No. 948) UV Spectrophotometer |
| Gabapentin Capsules | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Meropenem for injection | Pharmaceutical Testing | Identification & Assay | 90-120% (USP 2022) HPLC Method |
| Naproxen Sodium Tablets | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Lisinopril Tablets | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Ibuprofen oral Suspension | Pharmaceutical Testing | Identification & Assay | 90- 110% (USP 2022) HPLC Method |
| Dexamethasone sodium Phosphate Injection | Pharmaceutical Testing | Identification & Assay | 90-115% (USP 2022) HPLC Method |
| Paracetamol oral Suspension | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Mefenamic Acid Tablet | Pharmaceutical Testing | Assay | 95-105% (BP 2022 Vol-III Pg. No. 921) Titration |
| Cetirizine HCl Tablet | Pharmaceutical Testing | Identification & Assay | 90-110% (USP 2022) HPLC Method |
| Paracetamol Tablets | Pharmaceutical Testing | Dissolution | NLT 80% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |
| Levofloxacin Tablets | Pharmaceutical Testing | Dissolution | NLT 80% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |

13-12-2022
Date

SD
Director



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 162

| | | | |
|--|------------------------|------------------------|---|
| Amoxicillin Capsules | Pharmaceutical Testing | Dissolution | NLT 80% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |
| Ibuprofen Tablet | Pharmaceutical Testing | Dissolution | NLT 80% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |
| Ciprofloxacin Tablets | Pharmaceutical Testing | Dissolution | NLT 80% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |
| Metronidazole Tablets | Pharmaceutical Testing | Dissolution | NLT 85% (Q) (USP 2022) Dissolution/ UV Spectrophotometer |
| Isoflurane | Pharmaceutical Testing | Identification | USP 2022 FTIR |
| Atorvastatin Calcium Tablet | Pharmaceutical Testing | Identification & Assay | 94.5 – 105% (USP 2022) HPLC Method |
| Ciprofloxacin Infusion | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Ciprofloxacin Tablet | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Carbamazepine Tablets | Pharmaceutical Testing | Identification & Assay | 92 – 108% (USP 2022) HPLC |
| Phenytoin Sodium Injection | Pharmaceutical Testing | Identification & Assay | 95 – 105% (USP 2022) HPLC Method |
| Aspirin Gastro-resistant Tablets | Pharmaceutical Testing | Assay | 95 – 105% (BP 2022) HPLC Method |
| Glimepiride Tablets | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Ketorolac Tromethamine Injection | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Tranexamic Acid Injection | Pharmaceutical Testing | Assay | 95 – 105% (BP 2022) HPLC Method |
| Diclofenac Sodium Delayed-Release Tablet | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Diclofenac Potassium Tablet | Pharmaceutical Testing | Identification & Assay | 90 – 110% (USP 2022) HPLC |
| Hemodialysis Solution | Pharmaceutical Testing | Assay of Chlorides | 95 - 105% EP/BP 2022 Potentiometric Titration |
| | Pharmaceutical Testing | Assay of Bicarbonates | |
| | Pharmaceutical Testing | Assay of Acetate | |
| Risperidone Tablet | Pharmaceutical Testing | ID & Assay | 90 – 110% (USP 2022) HPLC |

13-12-2022

Date

SD

Director



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 162

| | | | |
|---|------------------------|-------------------------------|---|
| Co-Amoxiclav Injection | Pharmaceutical Testing | ID & Assay of Amoxicillin | 90 – 107.5% (BP 2022) HPLC |
| | Pharmaceutical Testing | ID & Assay of Clavulanic Acid | |
| Piperacillin and Tazobactam for Injection | Pharmaceutical Testing | ID & Assay of Piperacillin | 90 – 110% (USP 2022) HPLC |
| | Pharmaceutical Testing | ID & Assay of Tazobactam | |
| Atorvastatin Calcium Tablet USP | Pharmaceutical Testing | Dissolution | (USP 2022) Dissolution/ UV Spectrophotometer |
| Carbamazepine Tablets | Pharmaceutical Testing | Dissolution | (USP 2022) Dissolution/ UV Spectrophotometer |
| Risperidone Tablet | Pharmaceutical Testing | Dissolution | (USP 2022) Dissolution/ HPLC |
| Isoflurane USP | Pharmaceutical Testing | Refractive Index | USP 2022 Refractometer |
| Sodium Chloride + Glucose Infusion | Pharmaceutical Testing | Assay of Glucose | 95 - 105% (BP) Polarimeter |
| Glucose Infusion | Pharmaceutical Testing | Assay of Glucose | 95 - 105% (BP/USP) Polarimeter |
| Iron Sucrose Injection USP | Pharmaceutical Testing | Assay of Iron | 95 – 105% (USP 2022) AAS |
| Povidone-Iodine Solution USP | Pharmaceutical Testing | Assay | 85 – 120% (USP 2022) Potentiometric Titration |
| Lactated Ringer Injection USP | Pharmaceutical Testing | Assay of Potassium | 14.2–17.3mg/100mL (USP 2022) Flame Photometer |
| Water Determination | Pharmaceutical Testing | Water by Karl Fischer | USP 2022 <921> Method-I (Titrimetric) |
| Pharmaceutical Tablets | Pharmaceutical Testing | Hardness | USP 2022 <1217> |
| Pharmaceutical Tablets | Pharmaceutical Testing | Thickness | USP 2022 <1217> |
| Pharmaceutical Tablets | Pharmaceutical Testing | Diameter | USP 2022 <1217> |

13-12-2022

Date

SD

Director